World Health Organization Sounds Alert Over Critical Lack of Obesity Jabs

Under a tenth of people that would benefit from GLP-1 drugs including Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the drugs.

Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just availability to this class of drugs.

Based on estimates, more than two billion are projected to be obese by 2030 unless action is taken.

"The latest guidance recognises that excess weight is a lifelong illness that can be treated with thorough and lifelong support," said its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant obstacles to universal access to the jabs that can help people shift considerable body mass, notes the organization.

GLP-1 Therapy Scarcity

Even under the current most favorable outlook, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO.

The advice urges countries and companies to expand availability, through strategies like patent sharing.

Exclusive production rights on a key compound – the primary ingredient of a leading brand – is scheduled to end in multiple nations in 2026.

How Obesity Drugs Operate

The injections replicate a biological compound to reduce digestion speed, reduce hunger and boost satiety so users consume fewer calories.

People usually begin shedding pounds within a few weeks of commencing the weekly injections.

Studies suggests users may put most of the weight back on a year later of discontinuing the medication, because their usual food cravings resume.

To be carrying excess weight elevates your risk for experiencing medical conditions, such as diabetes, heart disease, stroke, and certain malignancies.

Excess weight concerns individuals in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.